Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Inclusion Criteria:

• Age 18-85 ;
• Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
• Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.

Exclusion Criteria:

• Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
• The presence of a contraindication to thrombolytic therapy of ischemic stroke;
• Pregnancy or lactation.